ORGO

SEC source: 0001062993-22-013879 · form4.xml · nonDerivative · entry 1

Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 459,444

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001062993-22-013521 · form4.xml · derivative · entry 12

Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 474,138

Underlying: Class A Common Stock · 84,674 shares

Expires 2024-08-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable.

SEC source: 0001062993-22-013521 · form4.xml · nonDerivative · entry 8

Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 398,242

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2022.

F5 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.47 to $5.72, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4.

SEC source: 0001062993-22-013521 · form4.xml · nonDerivative · entry 7

Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 482,916

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001062993-22-013521 · form4.xml · derivative · entry 11

Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 558,812

Underlying: Class A Common Stock · 52,312 shares

Expires 2024-08-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable.

SEC source: 0001062993-22-013521 · form4.xml · nonDerivative · entry 6

Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 398,242

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2022.

F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.60 to $5.73, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.

SEC source: 0001062993-22-013521 · form4.xml · nonDerivative · entry 5

Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 450,554

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001062993-22-013521 · form4.xml · derivative · entry 10

Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 611,124

Underlying: Class A Common Stock · 53,680 shares

Expires 2024-08-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable.

SEC source: 0001062993-22-013521 · form4.xml · derivative · entry 9

Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,067,245

Underlying: Class A Common Stock · 6,670 shares

Expires 2024-12-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable.

SEC source: 0001062993-22-013521 · form4.xml · nonDerivative · entry 4

Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 398,242

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2022.

F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.705 to $5.93, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.

SEC source: 0001062993-22-013521 · form4.xml · nonDerivative · entry 3

Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 451,922

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2022.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.70 to $6.05, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

SEC source: 0001062993-22-013521 · form4.xml · nonDerivative · entry 2

Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 458,592

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001062993-22-013521 · form4.xml · nonDerivative · entry 1

Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 404,912

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001062993-22-013178 · form4.xml · derivative · entry 9

Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,073,915

Underlying: Class A Common Stock · 58,654 shares

Expires 2024-12-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable.

SEC source: 0001062993-22-013178 · form4.xml · nonDerivative · entry 6

Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 398,242

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2022.

F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.75 to $6.04, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.

SEC source: 0001062993-22-013178 · form4.xml · nonDerivative · entry 5

Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 456,896

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001062993-22-013178 · form4.xml · derivative · entry 8

Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,132,569

Underlying: Class A Common Stock · 118,504 shares

Expires 2024-12-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable.

SEC source: 0001062993-22-013178 · form4.xml · nonDerivative · entry 4

Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 398,242

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2022.

F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.45 to $6.11, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.

SEC source: 0001062993-22-013178 · form4.xml · nonDerivative · entry 3

Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 516,746

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001062993-22-013178 · form4.xml · derivative · entry 7

Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,251,073

Underlying: Class A Common Stock · 86,531 shares

Expires 2024-12-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable.

SEC source: 0001062993-22-013178 · form4.xml · nonDerivative · entry 2

Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 398,242

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2022.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.39 to $5.62, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

SEC source: 0001062993-22-013178 · form4.xml · nonDerivative · entry 1

Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 484,773

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001062993-22-012849 · form4.xml · derivative · entry 12

Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,337,604

Underlying: Class A Common Stock · 98,078 shares

Expires 2024-12-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable.

SEC source: 0001062993-22-012849 · form4.xml · nonDerivative · entry 8

Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 398,242

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2022.

F5 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.83 to $6.06, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4.

SEC source: 0001062993-22-012849 · form4.xml · nonDerivative · entry 7

Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 496,320

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001062993-22-012849 · form4.xml · derivative · entry 11

Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,435,682

Underlying: Class A Common Stock · 80,369 shares

Expires 2024-12-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable.

SEC source: 0001062993-22-012849 · form4.xml · nonDerivative · entry 6

Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 398,242

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2022.

F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.77 to $6.13, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.

SEC source: 0001062993-22-012849 · form4.xml · nonDerivative · entry 5

Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 478,611

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001062993-22-012917 · form4.xml · nonDerivative · entry 3

KATZ MICHAEL W · CIK 0001279930 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,382

SEC source: 0001062993-22-012917 · form4.xml · nonDerivative · entry 2

KATZ MICHAEL W · CIK 0001279930 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,382

SEC source: 0001062993-22-012917 · form4.xml · nonDerivative · entry 1

KATZ MICHAEL W · CIK 0001279930 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,382

SEC source: 0001062993-22-012849 · form4.xml · derivative · entry 10

Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,516,051

Underlying: Class A Common Stock · 121,580 shares

Expires 2024-12-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable.

SEC source: 0001062993-22-012849 · form4.xml · derivative · entry 9

Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 505,050

Underlying: Class A Common Stock · 14,810 shares

Expires 2023-07-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable.

SEC source: 0001062993-22-012849 · form4.xml · nonDerivative · entry 4

Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 398,242

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2022.

F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $6.06 to $6.32, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.

SEC source: 0001062993-22-012849 · form4.xml · nonDerivative · entry 3

Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 519,822

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2022.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $6.01 to $6.16, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

SEC source: 0001062993-22-012849 · form4.xml · nonDerivative · entry 2

Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 534,632

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001062993-22-012849 · form4.xml · nonDerivative · entry 1

Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 413,052

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001062993-22-011685 · form4.xml · nonDerivative · entry 1

Quintero Gilberto · CIK 0001927023 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,913

F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on May 3, 2023.

SEC source: 0001062993-22-011683 · form4.xml · nonDerivative · entry 1

Korfin Michele Ilene · CIK 0001771664 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,913

F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on May 3, 2023.

SEC source: 0001062993-22-009813 · form4.xml · nonDerivative · entry 1

Montecalvo Antonio S. · CIK 0001759261 · Vice President, Health Policy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,551

SEC source: 0001062993-22-009811 · form4.xml · nonDerivative · entry 1

Freedman Lori · CIK 0001410291 · VP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,845

SEC source: 0001062993-22-009817 · form4.xml · nonDerivative · entry 1

Grow Brian · CIK 0001759142 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 86,939

SEC source: 0001062993-22-009815 · form4.xml · nonDerivative · entry 1

Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 398,242

SEC source: 0001062993-22-009807 · form4.xml · nonDerivative · entry 1

Bilbo Patrick · CIK 0001759203 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 183,162

SEC source: 0001062993-22-007530 · form4.xml · derivative · entry 6

Montecalvo Antonio S. · CIK 0001759261 · Vice President, Health Policy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 78,175

Underlying: Class A Common Stock · 22,401 shares

Expires 2027-05-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The shares underlying the option vested or shall vest 20% annually beginning on December 31, 2017.

SEC source: 0001062993-22-007530 · form4.xml · derivative · entry 5

Montecalvo Antonio S. · CIK 0001759261 · Vice President, Health Policy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,397

Underlying: Class A Common Stock · 46,103 shares

Expires 2027-05-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The shares underlying the option vested or shall vest 20% annually beginning on January 1, 2018.

SEC source: 0001062993-22-007530 · form4.xml · nonDerivative · entry 4

Montecalvo Antonio S. · CIK 0001759261 · Vice President, Health Policy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,289

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $8.34 to $8.42, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

SEC source: 0001062993-22-007530 · form4.xml · nonDerivative · entry 3

Montecalvo Antonio S. · CIK 0001759261 · Vice President, Health Policy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 141,725

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001062993-22-007530 · form4.xml · nonDerivative · entry 2

Montecalvo Antonio S. · CIK 0001759261 · Vice President, Health Policy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 119,324

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001062993-22-007530 · form4.xml · nonDerivative · entry 1

Montecalvo Antonio S. · CIK 0001759261 · Vice President, Health Policy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,221

F1 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $8.50 to $8.54, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.